Literature DB >> 11923061

Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine.

Sumithra Gopal1, Tsang-Bin Tzeng, Alan Cowan.   

Abstract

The purpose of this project was to characterize the dose-dependent pharmacokinetics of buprenorphine (BN) and norbuprenorphine (NBN), the primary metabolite, after intravenous administration of different doses of BN to rats. Adult male Sprague-Dawley rats were divided into six groups and received a single intravenous bolus dose of 0.1, 0.3, 1, 3, 10 or 30 mg/kg of BN. A separate study was performed where BN and NBN were simultaneously administered intravenously (1 mg/kg+1 mg/kg). Plasma samples were obtained by centrifugation of the blood and analyzed for BN and NBN using a sensitive and selective gas chromatographic-mass spectrometric (GC-MS) bio-analytical method. Noncompartmental and compartmental methods were used to perform pharmacokinetic data analysis. BN declined triexponentially with a dose-dependent increase in its volume of distribution, V(ss) (8.37-18.2 l/kg) and clearance CL (2.70-6.10 l/h per kg). The pharmacokinetics of NBN were linear and biexponential. Coadministration of BN and NBN resulted in a significant increase in the volume of distribution and clearance of BN. The present results suggest that the nonlinear disposition in the clearance and volume of distribution of BN can be attributed, in part, to the increasing concentration of the metabolite.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11923061     DOI: 10.1016/s0928-0987(02)00009-x

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  10 in total

1.  The effects of buprenorphine on fentanyl withdrawal in rats.

Authors:  Adrie W Bruijnzeel; Catherine Marcinkiewcz; Shani Isaac; Matthew M Booth; Donn M Dennis; Mark S Gold
Journal:  Psychopharmacology (Berl)       Date:  2007-01-09       Impact factor: 4.530

2.  In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome.

Authors:  Bryce A Griffin; Caitlin O Caperton; Lauren N Russell; Christian V Cabanlong; Catheryn D Wilson; Kyle R Urquhart; Bradford S Martins; Marcelle Dina Zita; Amy L Patton; Alexander W Alund; S Michael Owens; William E Fantegrossi; Jeffery H Moran; Lisa K Brents
Journal:  J Pharmacol Exp Ther       Date:  2019-04-26       Impact factor: 4.030

3.  Voluntary Running-Wheel Activity, Arterial Blood Gases, and Thermal Antinociception in Rats after 3 Buprenorphine Formulations.

Authors:  Rebecca A Johnson
Journal:  J Am Assoc Lab Anim Sci       Date:  2016       Impact factor: 1.232

4.  Evaluation of a sustained-release formulation of buprenorphine for analgesia in rats.

Authors:  Patricia L Foley; Haixiang Liang; Andrew R Crichlow
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-03       Impact factor: 1.232

5.  Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport.

Authors:  Tim Quach; Luojuan Hu; Sifei Han; Shea F Lim; Danielle Senyschyn; Preeti Yadav; Natalie L Trevaksis; Jamie S Simpson; Christopher J H Porter
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

6.  Evaluation of buprenorphine hydrochloride Pluronic(®) gel formulation in male C57BL/6NCrl mice.

Authors:  Terry L Blankenship-Paris; John W Dutton; David R Goulding; Christopher A McGee; Grace E Kissling; Page H Myers
Journal:  Lab Anim (NY)       Date:  2016-09-21       Impact factor: 12.625

7.  Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats.

Authors:  Lindsey R Hammerslag; Rebecca S Hofford; Qiwen Kang; Richard J Kryscio; Joshua S Beckmann; Michael T Bardo
Journal:  Drug Alcohol Depend       Date:  2019-12-16       Impact factor: 4.492

8.  Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.

Authors:  Nora M Hagelberg; Mari Fihlman; Tuija Hemmilä; Janne T Backman; Jouko Laitila; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola; Teijo I Saari
Journal:  Pharmacol Res Perspect       Date:  2016-11-03

9.  Mitragynine Attenuates Morphine Withdrawal Effects in Rats-A Comparison With Methadone and Buprenorphine.

Authors:  Rahimah Hassan; Cheah Pike See; Sasidharan Sreenivasan; Sharif M Mansor; Christian P Müller; Zurina Hassan
Journal:  Front Psychiatry       Date:  2020-05-07       Impact factor: 4.157

10.  Design and in vivo evaluation of a microparticulate depot formulation of buprenorphine for veterinary use.

Authors:  Viktoria Schreiner; Mattea Durst; Margarete Arras; Pascal Detampel; Paulin Jirkof; Jörg Huwyler
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.